Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Matoba

Showing results (71-80 of 166) with videos related to

Pageof 17
Sort By:
Circulation. Cardiovascular Interventions|September 3, 2021
Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE TrialKoichi Kaikita, Satoshi Yasuda, Masaharu Akao, et al.
The New England Journal of Medicine|September 3, 2019
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary DiseaseSatoshi Yasuda, Koichi Kaikita, Masaharu Akao, et al.
American Heart Journal|March 3, 2021
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysisMasaharu Akao, Satoshi Yasuda, Koichi Kaikita, et al.
International Journal of Cardiology|May 17, 2018
Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group studySatoshi Yasuda, Koichi Kaikita, Hisao Ogawa, et al.
BMC Medicine|February 25, 2022
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trialKunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, et al.
Scientific Reports|July 13, 2016
Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated InflammationYasuhiro Nakano, Tetsuya Matoba, Masaki Tokutome, et al.
Scientific Reports|September 4, 2020
Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia-reperfusion injuryArihide Okahara, Jun-Ichiro Koga, Tetsuya Matoba, et al.
JAMA Cardiology|June 15, 2022
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE TrialRyo Naito, Katsumi Miyauchi, Satoshi Yasuda, et al.
Circulation Reports|June 11, 2024
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan　- Analysis From the JROAD-DPC DatabaseMitsukuni Kimura, Tetsuya Matoba, Yasuhiro Nakano, et al.
Journal of the American Heart Association|October 18, 2021
Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE TrialYasushi Matsuzawa, Kazuo Kimura, Satoshi Yasuda, et al.
Pageof 17

Showing results (71-80 of 166) with videos related to

Sort By:
Pageof 17
Circulation. Cardiovascular Interventions|September 3, 2021
Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE TrialKoichi Kaikita, Satoshi Yasuda, Masaharu Akao, et al.
The New England Journal of Medicine|September 3, 2019
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary DiseaseSatoshi Yasuda, Koichi Kaikita, Masaharu Akao, et al.
American Heart Journal|March 3, 2021
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysisMasaharu Akao, Satoshi Yasuda, Koichi Kaikita, et al.
International Journal of Cardiology|May 17, 2018
Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group studySatoshi Yasuda, Koichi Kaikita, Hisao Ogawa, et al.
BMC Medicine|February 25, 2022
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trialKunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, et al.
Scientific Reports|July 13, 2016
Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated InflammationYasuhiro Nakano, Tetsuya Matoba, Masaki Tokutome, et al.
Scientific Reports|September 4, 2020
Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia-reperfusion injuryArihide Okahara, Jun-Ichiro Koga, Tetsuya Matoba, et al.
JAMA Cardiology|June 15, 2022
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE TrialRyo Naito, Katsumi Miyauchi, Satoshi Yasuda, et al.
Circulation Reports|June 11, 2024
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan　- Analysis From the JROAD-DPC DatabaseMitsukuni Kimura, Tetsuya Matoba, Yasuhiro Nakano, et al.
Journal of the American Heart Association|October 18, 2021
Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE TrialYasushi Matsuzawa, Kazuo Kimura, Satoshi Yasuda, et al.
Pageof 17